ClinicalTrials.gg
CompletedNCT02397954Updated Mar 20, 2025Results posted

A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

A Phase 2 interventional study of Avacincaptad Pegol in Idiopathic Polypoidal Choroidal Vasculopathy, sponsored by Ophthotech Corporation. Completed at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-03-20.

Sponsored by Ophthotech Corporation (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Polypoidal Choroidal Vasculopathy · United States.

Enrollment
11th of 12
4 · median 20
Started
2015
the only one that year
Phase 2
3 of 13
none open now
Registered
12th of 13
by date
Lead sponsor
2 of 13
Ophthotech Corporation

Among the 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States, this one is the 11th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2015, is one of 3 in phase 2, and was the 12th registered.

Polypoidal Choroidal Vasculopathy

54 studies on the registry are indexed under Polypoidal Choroidal Vasculopathy; 6 are open to participants now.

Browse Polypoidal Choroidal Vasculopathy studies →

Open to participants now

1 of the 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Polypoidal Choroidal Vasculopathy studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States, or all of them as a file.
02

Study summary

The objectives of this study are to evaluate the safety and tolerability of Zimura™ intravitreous injection in combination with anti-vascular endothelial growth factor (VEGF) therapy in subjects with Idiopathic Polypoidal Choroidal Vasculopathy (IPCV).

Read the detailed description

Treatment experienced (Prior treatment with anti-VEGF monotherapy of ≥8 injections in the previous twelve (12) months) subjects of either gender aged 50 years or above with a diagnosis of IPCV, will receive 3 monthly (Q4W) intravitreal injections of Zimura™ (1 mg/eye) in combination with anti-VEGF therapy (Avastin® 1.25 mg/eye or Lucentis® 0.5 mg/eye or Eylea® 2 mg/eye).

Safety endpoints include visual acuity loss (proportion of subjects with >15 letter loss at Month 3), ophthalmic adverse events (AEs), systemic adverse events (AEs), change in total retinal thickness (SD-OCT) at Month 3, regression and/or elimination of polyps at Month 3 compared to screening as measured by indocyanine green angiography (ICGA), and laboratory values.

03

Conditions studied

  • Idiopathic Polypoidal Choroidal Vasculopathy

Keywords

  • idiopathic polypoidal choroidal vasculopathy
  • IPCV
  • Zimura™ (previous name)
  • Avastin®
  • Eylea®
  • Lucentis®
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects of either gender aged ≥ 50 years
  • Diagnosis of IPCV
  • Treatment-experienced defined as prior treatment with anti-VEGF mono therapy of ≥ 8 injections in the previous twelve (12) months

Exclusion criteria

Exclusion Criteria:

  • Any intraocular surgery or thermal laser within three (3) months of trial entry
  • Any prior thermal laser in the macular region, regardless of indication
  • Any ocular or periocular infection in the twelve (12) weeks prior to entry
  • History of any of the following conditions or procedures in the study eye: Rhegmatogenous retinal detachment, pars plana vitrectomy, filtering surgery (e.g. trabeculectomy), glaucoma drainage device, corneal transplant
  • Previous therapeutic radiation in the region of the study eye
  • A diagnosis of diabetic retinopathy (presence of microaneurysms or any vasculopathy and/or leakage from retinal vasculature in a subject with diabetes mellitus)
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Avacincaptad Pegol + Anti-VEGF

    Subjects will receive monthly intravitreous injections of Avacincaptad Pegol in combination with either Lucentis, Avastin or Eylea.

    Drug: Avacincaptad Pegol

Interventions

  • Subjects will receive monthly intravitreous injections of Avacincaptad Pegol in combination with Lucentis, Avastin or Eylea.

    Also known as: Zimura (previous name), IZERVAY, Avastin, Eylea, Lucentis, ARC1905

06

What researchers measure

Primary outcomes

  1. Number of Participants With >15 ETDRS Letter Loss at Month 3

    Number of participants with \>15 ETDRS letter loss (with calculated percentage)

    Time frame: 3 Months

  2. Number of Participants With Ophthalmic Adverse Events

    Number of Participants with Ophthalmic Adverse Events (with calculated percentage)

    Time frame: 3 months

  3. Number of Participants With Systemic Adverse Events

    Number of Participants with Systemic Adverse Events (with calculated percentage)

    Time frame: 3 months

Other outcomes

  1. Mean Change in Central Subfield Retinal Thickness (SD-OCT) From Baseline at Month 3

    Mean change in central subfield retinal thickness from baseline at Month 3 as measured by SD-OCT

    Time frame: Baseline and Month 3

  2. Regression and/or Elimination of Polyps at Month 3

    Regression and/or Elimination of Polyps from baseline to Month 3

    Time frame: Baseline and Month 3

07

Results

Posted Jan 23, 2019

Participant flow

Participant flow — Overall Study
MilestoneZimura + Anti-VEGF
Started4
Completed4
Not completed0

Outcome measures

PrimaryNumber of Participants With >15 ETDRS Letter Loss at Month 3

Number of participants with \>15 ETDRS letter loss (with calculated percentage)

Time frame:
3 Months
Reported as:
Count of participants · Participants
Number of Participants With >15 ETDRS Letter Loss at Month 3
ParticipantsZimura + Anti-VEGF
Number of Participants With >15 ETDRS Letter Loss at Month 30
PrimaryNumber of Participants With Ophthalmic Adverse Events

Number of Participants with Ophthalmic Adverse Events (with calculated percentage)

Time frame:
3 months
Reported as:
Count of participants · Participants
Number of Participants With Ophthalmic Adverse Events
ParticipantsZimura + Anti-VEGF
Number of Participants With Ophthalmic Adverse Events3
PrimaryNumber of Participants With Systemic Adverse Events

Number of Participants with Systemic Adverse Events (with calculated percentage)

Time frame:
3 months
Reported as:
Count of participants · Participants
Number of Participants With Systemic Adverse Events
ParticipantsZimura + Anti-VEGF
Number of Participants With Systemic Adverse Events1
Other pre-specifiedMean Change in Central Subfield Retinal Thickness (SD-OCT) From Baseline at Month 3

Mean change in central subfield retinal thickness from baseline at Month 3 as measured by SD-OCT

Time frame:
Baseline and Month 3
Reported as:
Mean · μm
Mean Change in Central Subfield Retinal Thickness (SD-OCT) From Baseline at Month 3
μmZimura + Anti-VEGF
Mean Change in Central Subfield Retinal Thickness (SD-OCT) From Baseline at Month 3-2.75 (-67 to 69)
Other pre-specifiedRegression and/or Elimination of Polyps at Month 3

Regression and/or Elimination of Polyps from baseline to Month 3

Time frame:
Baseline and Month 3
Reported as:
Number · Polyps
Regression and/or Elimination of Polyps at Month 3
PolypsZimura + Anti-VEGF
Regression and/or Elimination of Polyps at Month 3NA

Adverse events

Collected over 3 Months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zimura + Anti-VEGF0/4 (0%)1/4 (25%)3/4 (75%)
Most frequent serious events
Most frequent serious events
EventZimura + Anti-VEGF
EndophthalmitisInfections and infestations1/4
Most frequent other events
Most frequent other events
EventZimura + Anti-VEGF
Conjunctival haemorrhageEye disorders3/4
Gastroesophageal reflux diseaseGastrointestinal disorders1/4

Baseline characteristics

Age, Continuous
Age, Continuous(years)Zimura + Anti-VEGF
Mean74.5 ± 6.03
Age, Customized
Age, Customized(Participants)Zimura + Anti-VEGF
Age — Adults 50-650
Age — Adults >65-752
Age — Adults >752
Sex: Female, Male
Sex: Female, Male(Participants)Zimura + Anti-VEGF
Female1
Male3
Region of Enrollment
Region of Enrollment(participants)Zimura + Anti-VEGF
United States4
08

Study locations

1 site
  • Phoenix, Arizona 85014, United States
09

References and documents

Publications

  • Park EJ, Choi J, Lee KC, Na DH. Emerging PEGylated non-biologic drugs. Expert Opin Emerg Drugs. 2019 Jun;24(2):107-119. doi: 10.1080/14728214.2019.1604684. Epub 2019 Apr 19. PubMed 30957581 ↗

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2015 to primary completion in Oct 2015, 7 months.

Results were first posted in Jan 2019, 3 years 3 months after primary completion. A results delay was requested in Apr 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2015
First posted
Mar 25, 2015
StartActual
Mar 12, 2015
Primary completionActual
Oct 23, 2015
CompletionActual
Oct 23, 2015
Results delay requested
Apr 4, 2017
Results first posted
Jan 23, 2019
Last update
Mar 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02397954
Responsible party
Sponsor
First posted
Mar 25, 2015
Start date
Mar 12, 2015
Primary completion
Oct 23, 2015
Completion
Oct 23, 2015
Results posted
Jan 23, 2019
Last update
Mar 20, 2025

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avacincaptad pegol

Start the discussion